ASCO GU 2025 had groundbreaking advancements in genitourinary cancer treatments, focusing on prostate cancer, renal cell ...

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous formulation for the treatment of adult patients ...

Many people with prostate cancer experience fatigue as a symptom of the cancer and as a side effect of treatment. In fact, up to 90 percent of men with prostate cancer experience fatigue.

Johnson & Johnson’s sNDA for Akeega gets US FDA approval to treat patients with BRCA2-mutated mCSPC: Horsham, Pennsylvania Wednesday, December 17, 2025, 13:00 Hrs [IST] Johnson ...

Nollywood legends. From veteran actors like Fibian Adibe to rising stars such as Odira Nwobu the industry mourns its greats.

Celcuity Inc. soared on best-in-class Phase 3 breast cancer data. Click to see why I have a Buy rating on CELC due to data, ...

IS YOUR sex life more flat than fire? The reason could be closer than you think. In fact, it could be sitting in your ...

“Following the initial pause, the FDA has placed the trial on a partial clinical hold,” the spokesperson explained.

Astellas and Pfizer announced that neoadjuvant plus adjuvant enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) ...

Our Cycling Lifestyle Editor Ron, get's up close and personal as he gives out his unique picks for Editor's Choice Awards.

Detailed price information for GT Biopharma Inc (GTBP-Q) from The Globe and Mail including charting and trades.